The Preventive Role of mRNA Vaccines in Reducing Death among Moderate Omicron-Infected Patients: A Follow-Up Study

Very few studies have been conducted to assess the potential preventive role of vaccines, particularly mRNA vaccines, in the improvement of survival among moderate and severe hospitalized patients with COVID-19. After community-acquired outbreaks of the Omicron variant from 18 March until 31 May 202...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2022-11, Vol.14 (12), p.2622
Main Authors: Yen, Amy Ming-Fang, Chen, Sam Li-Sheng, Hsu, Chen-Yang, Chen, Tony Hsiu-Hsi
Format: Article
Language:English
Subjects:
Age
Coronaviruses
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
Death
Disease control
Disease prevention
Drug dosages
Drug therapy
Epidemics
Fatalities
Follow-Up Studies
Hospital patients
Hospitalization
Hospitals
Humans
Immunization
mRNA
mRNA Vaccines
Older people
Omicron
preventive effect
Retrospective Studies
SARS-CoV-2 - genetics
Severe acute respiratory syndrome coronavirus 2
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Very few studies have been conducted to assess the potential preventive role of vaccines, particularly mRNA vaccines, in the improvement of survival among moderate and severe hospitalized patients with COVID-19. After community-acquired outbreaks of the Omicron variant from 18 March until 31 May 2022, occurred in Taiwan, this retrospective cohort of 4090 moderate and 1378 severe patients admitted to hospital was classified according to whether they were administered an mRNA-based vaccine, and followed up to ascertain rates of death in both the vaccinated (≥2 doses) and unvaccinated (no or 1 dose) groups. The age-adjusted hazard ratio (aHR) of less than 1 was used to assess the preventive role of mRNA vaccines in reducing deaths among moderate and severe Omicron-infected patients. Survival was statistically significantly better for the ≥2 dose jab group (aHR, 0.75, 95% confidence interval [CI], 0.60 to 0.94) and even higher among those who had received a booster jab (aHR, 0.71; 95% CI, 0.55 to 0.91) compared with the unvaccinated group among moderate patients, but not among severe patients. In conclusion, unveiling the role of mRNA vaccines in preventing moderate but not severe COVID-19 patients from death provides new insights into how mRNA vaccines play a role in the pathway leading to a severe outcome due to Omicron COVID-19.
ISSN:1999-4915
1999-4915
DOI:10.3390/v14122622